Literature DB >> 1374016

Galanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-I(7-37) in mouse insulinoma beta TC-1 cells.

H C Fehmann1, J F Habener.   

Abstract

The neuropeptide hormone galanin, released by sympathetic stimulation of nerve terminals in the endocrine pancreas, inhibits insulin secretion via a receptor-linked pertussis toxin-sensitive (Gi) transmembrane signaling pathway. Glucagon-like peptide-I(7-37) [GLP-I(7-37)] is an intestinal hormone shown to have potent insulin-releasing activities in pancreatic B-cells and is believed to serve a physiological role in the augmentation of nutrient-induced insulin release. GLP-I(7-37) binds to specific Gs- and adenylate cyclase-coupled receptors on pancreatic B-cells and directly stimulates proinsulin gene transcription, thereby increasing cellular levels of proinsulin messenger RNA (mRNA) and proinsulin biosynthesis. This study examines the effects of galanin on GLP-I(7-37)-stimulated proinsulin gene expression in mouse beta TC1 cells. The degree of proinsulin gene transcription was assessed by measuring the activity of chloramphenicol acetyl transferase (CAT) expressed from a CAT reporter plasmid linked to the rat insulin-1 gene promoter transferred to beta TC1 cells and by measuring proinsulin mRNA levels by Northern blot analysis. Galanin inhibited both CAT activity and the rise in proinsulin mRNA levels stimulated by either GLP-I(7-37) or forskolin (0.1 microM). Notably, galanin was without effect on CAT activity induced by the cAMP analog, 8-bromo-cAMP, the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, or higher concentrations of forskolin. The inhibitory effects of galanin on GLP-I(7-37) and forskolin-induced CAT activity were reversed by the addition of pertussis toxin, a toxin that inactivates inhibitory G-proteins (Gi). We conclude that galanin inhibits GLP-I(7-37)-stimulated proinsulin gene expression by inhibiting the activation of adenylate cyclase by GLP-I(7-37) and subsequently the production of cAMP in B-cells. Further, our data suggest that these actions of galanin are mediated by a pertussis toxin sensitive pathway involving one or more Gis that inhibit adenylate cyclase. Thus, in addition to its well known inhibitory effects on insulin secretion galanin can inhibit proinsulin gene expression stimulated by GLP-I(7-37) activation of the cAMP signaling pathway. These findings may be a unique demonstration of the inhibition of proinsulin gene expression by a substance (galanin) released endogenously within the pancreas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374016     DOI: 10.1210/endo.130.5.1374016

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.

Authors:  G Skoglund; M A Hussain; G G Holz
Journal:  Diabetes       Date:  2000-07       Impact factor: 9.461

Review 3.  Galanin--a neuropeptide with inhibitory actions.

Authors:  K Kask; U Langel; T Bartfai
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

4.  Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells.

Authors:  J B Redmon; L K Olson; M B Armstrong; M J Greene; R P Robertson
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

5.  Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice.

Authors:  Hanlin Zhang; Meng Dong; Shouli Yuan; Wanzhu Jin
Journal:  Biotechnol Lett       Date:  2022-08-25       Impact factor: 2.716

6.  Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells.

Authors:  H C Fehmann; M Janssen; B Göke
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

7.  Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists.

Authors:  Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2009-12-30

Review 8.  Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

Authors:  Curtis Triplitt; Eugenio Cersosimo; Ralph A DeFronzo
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

Review 9.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.